4DMedical wins commercial contract with IPOC

25 November 2024

Highlights

- 4DMedical enters commercial contract with U.S.-based radiology provider, IPOC
- Reimbursement and education event for referring specialists key to activation
- Contract demonstrates the appeal of 4DMedical's approach of combined structural and functional lung analysis tools for U.S. clinicians and their patients

Melbourne, Australia, **25 November 2024**: 4DMedical Limited (ASX: 4DX) ("4DMedical" or the "Company"), a leader in respiratory imaging and analysis, today announces the signing of a commercial contract with Imaging Partners of Orange County (IPOC) in the United States to provide CT LVAS™ and LDAf (Lung Density Analysis™) scans.

Commercial contract with comprehensive imaging provider IPOC

This partnership marks 4DMedical's first commercial contract with an independent radiology provider since the Centers for Medicare & Medicaid Services (CMS) awarded reimbursement for CT LVAS™, signalling accelerated progress in the commercialisation of the Company's lung imaging technology. The contract term extends through to March 31, 2026 and provides IPOC with scan analysis, on a subscription basis per patient, billed quarterly.

With 15 radiologists across five sites, IPOC provides radiology services across the communities of Orange County. Orange County is renowned for its outstanding healthcare sector, with a strong emphasis on medical innovation, including cutting-edge research institutions alongside world-class hospitals.

This development follows a recent webinar co-hosted by the California Thoracic Society (CTS), the Californian branch of the American Thoracic Society, which focused on the application of CT-based imaging for triaging unexplained dyspnoea. The webinar, aimed at pulmonologists and respiratory health specialists, generated significant interest from clinicians seeking to leverage advanced imaging technologies to enhance diagnostic pathways for patients with undiagnosed respiratory conditions.

4DMedical's CT LVAS™ technology provides a detailed analysis of lung ventilation and airflow, assisting clinicians in diagnosing and assessing respiratory diseases more effectively than traditional methods. The addition of LDAf allows physicians to quantify lung structure, which side by side with lung function, adds significant value in identifying and managing obstructive lung diseases.

4DMedical MD/CEO and Founder Andreas Fouras said:

We are thrilled to secure this commercial contract with IPOC and are encouraged by rapidly growing interest from pulmonologists in the United States, particularly after our recent educational initiatives with CTS. With U.S. reimbursement for CT LVAS™ now established, this contract further validates our technology's value in the clinical setting and strengthens our position in the market as we work to improve diagnostic options for patients suffering from unexplained dyspnoea and other respiratory ailments.

This agreement with IPOC, on the back of the announcement of a commercial contract with UCSD, underscores the growing demand for our innovative respiratory imaging solutions.

We have an incredibly busy end to the year, including RSNA in early December. I look forward to updating you on that, and other commercial activity, as we push hard into the end of 2024.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate	**Administration**	**Media Enquiries**
Chief Financial Officer	Company Secretary	4Dmedia@4dmedical.com
Simon Glover	Naomi Lawrie	
sglover@4dmedical.com	companysecretary@4dmedical.com	

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity, and more personalised care for patients.

To learn more, please visit www.4dmedical.com